
Myriad Genetics (MYGN) Stock Forecast & Price Target
Myriad Genetics (MYGN) Analyst Ratings
Bulls say
Myriad Genetics Inc has demonstrated robust growth within its Pharmacogenomics segment, reporting a 14% year-over-year increase in 2024, with GeneSight specifically achieving a 23% growth rate. Additionally, the company's prenatal testing services, including Prequel and Foresight tests, have experienced a combined growth rate of 12% year-over-year in the fourth quarter of 2024, and 17% growth for the full fiscal year 2024. With anticipated new product launches, particularly an expansion of hereditary cancer screening in the second half of 2025 and a promising outlook for continued growth in prenatal testing, Myriad Genetics is well-positioned to capitalize on market opportunities and sustain its momentum above historical growth rates.
Bears say
Myriad Genetics has faced significant setbacks that could adversely affect its financial outlook, notably the loss of reimbursement from a private payer for its GeneSight product and a change in NCCN guideline language, which may result in reduced near-term revenues. The FY25 revenue guidance of $840M-$860M falls short of analyst consensus estimates, raising concerns about the company's ability to sustain organic growth amidst competitive pressures and regulatory risks. Furthermore, ongoing challenges in relationships with payors, potential product development failures, and anticipated price erosion pose considerable risks to the company's operating performance and overall market position.
This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.
Myriad Genetics (MYGN) Analyst Forecast & Price Prediction
Start investing in Myriad Genetics (MYGN)
Order type
Buy in
Order amount
Est. shares
0 shares